A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP

References

• Aspenstrom-Fagerlund B, Tallkvist J, Ilback NG, Glynn AW. (2012). Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers. Food Chem Toxicol 50:3635–45.
   PubMed Web of Science ®Google Scholar
• Caetano-Pinto P, Janssen MJ, Gijzen L, et al. (2016). Fluorescence-based transport assays revisited in a human renal proximal tubule cell line. Mol Pharmaceutics 13:933–44.
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. (2006). Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231–59.
   PubMed Web of Science ®Google Scholar
• Doyle L, Ross DD. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–58.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. (2004). The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42.
   PubMedGoogle Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Utsunomiya T, Inoue H, et al. (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506–13.
   PubMed Web of Science ®Google Scholar
• Hegedus C, Truta-Feles K, Antalffy G, et al. (2012). Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol 84:260–7.
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsukahara S, Asada S, Sugimoto Y. (2004). Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346–52.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Smit JW, Brinkhuis RF, et al. (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651–6.
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Beijnen JH, Rosing H, et al. (2002). Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. JCO 20:2943–50.
   PubMed Web of Science ®Google Scholar
• Liang E, Proudfoot J, Yazdanian M. (2000). Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 17:1168–74.
   PubMed Web of Science ®Google Scholar
• Mease K, Sane R, Podila L, Taub ME. (2012). Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci 101:1888–97.
   PubMed Web of Science ®Google Scholar
• Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. (2008). Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug–drug interactions. Pharm Res 25:2320–6.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, He H, Singh M, et al. (1998). Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850–8.
   PubMed Web of Science ®Google Scholar
• Riemer P, Rydenfelt M, Marks M, et al. (2017). Oncogenic beta-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. J Cell Biol 216:1567–77.
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, et al. (2009). ABCG2: a perspective. Adv Drug Deliv Rev 61:3–13.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Colman MJ, Schewe M, Meerlo M, et al. (2017). Interplay between metabolic identities in the intestinal crypt supports stem cell function. Nature 543:424–7.
   PubMed Web of Science ®Google Scholar
• Sato T, Vries RG, Snippert HJ, et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:262–5.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Oka M, Soda H, et al. (2004). Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146–51.
   PubMed Web of Science ®Google Scholar
• Son MY, Sim H, Son YS, et al. (2017). Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells. Neuropathol Appl Neurobiol [Epub ahead of print]. doi:10.1111/nan.12396.
   PubMed Web of Science ®Google Scholar
• Westover D, Li F. (2015). New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res 34:159.
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Nishiyama Y, Furuta T, et al. (2011). Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 10:1252–63.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han YJ, Zhang X, et al. (2016a). Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKalpha1 signalling in adipose tissue macrophages. Diabetologia 59:2219–28.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng Z, Zhao J, et al. (2016b). Measurement of rhodamine 123 in three-dimensional organoids: a novel model for P-glycoprotein inhibitor screening. Basic Clin Pharmacol Toxicol 119:349–52.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zeng Z, Sun J, et al. (2017). A novel model of P-glycoprotein inhibitor screening using human small intestinal organoids. Basic Clin Pharmacol Toxicol 120:250–5.
   PubMed Web of Science ®Google Scholar